// App-Quantinova.ai

: APABETALONE, AN EPIGENETIC BET INHIBITOR IN A PHASE 3 TRIAL, INHIBITS VASCULAR INFLAMMATION AND CELLULAR ADHESION LEADING TO BENEFICIAL OUTCOMES IN CVD PATIENTS

Researchers

Presenter

  • Laura Tsujikawa

Principal Investigators

  • Li Fu

  • Shovon Das

  • Brooke D. Rakai

  • Chris D. Sarsons

  • Christopher Halliday

  • Stephanie C. Stotz

  • Emily Daze

  • Sylwia Wasiak

  • Deborah Studer

  • Sam Dorosz

  • Kristina D. Rinker

  • Michael Sweeney

  • Jan O. Johansson

  • Norman Wong

  • Ewelina Kulikowski

Medical Centers

  • Resverlogix Corp., Calgary, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • RVX-208

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved